TargEDys
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|---|
Revenues | <1m | - | - | <1m | <1m | 1.2m | <1m |
% growth | - | - | - | - | 561 % | 562 % | (42 %) |
EBITDA | (<1m) | (1.1m) | (2.1m) | (2.8m) | (2.9m) | (1.6m) | (1.6m) |
% EBITDA margin | (71904 %) | - | - | (10391 %) | (1645 %) | (140 %) | (242 %) |
Profit | (<1m) | (1.0m) | (1.8m) | (2.3m) | (2.5m) | (1.4m) | (1.4m) |
% profit margin | (62840 %) | - | - | (8557 %) | (1413 %) | (121 %) | (208 %) |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | N/A | Support Program | |
€5.8m | Series A | ||
* | €1.1m Valuation: €29.0m -25.3x EV/LTM EBITDA | Early VC | |
* | €3.5m | Series A | |
* | N/A | Acquisition | |
Total Funding | AUD17.7m |
Recent News about TargEDys
EditTargEDys is a pioneering company specializing in microbiome-based solutions aimed at weight management and optimal nutrition. Operating within the healthcare and biotechnology sectors, TargEDys collaborates with renowned researchers to develop precision probiotics that target specific health outcomes. The company's unique approach is backed by 10 families of patents, ensuring robust intellectual property protection. TargEDys primarily serves healthcare providers, nutritionists, and consumers seeking scientifically-backed nutritional supplements. The business model revolves around research and development, patent licensing, and direct sales of their probiotic products. Revenue is generated through product sales, partnerships, and licensing agreements. TargEDys' commitment to innovation and scientific rigor positions it as a leader in the next generation of probiotics.
Keywords: microbiome, probiotics, weight management, nutrition, healthcare, biotechnology, precision probiotics, patent, research, innovation.